Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dyax Completes Rolling BLA For HAE Candidate DX-88

This article was originally published in The Pink Sheet Daily

Executive Summary

Company seeks priority review, which if granted could set an FDA action date in March.

Related Content

Dyax’s Acute HAE Candidate Faces Efficacy And Risk Hurdles At Panel Review
Advisory committee to assess DX-88 for HAE
ViroPharma Sets High Pricing For Cinryze, Unveils Promotional Plan
Cinryze Prophylaxis Approval Leaves Window For HAE Treatment Contenders
Sales Growth Leaves Analysts Bullish On Cubist’s Cubicin
Shire Likely To Liquidate Jerini Holdings Except Firazyr
Dyax’s HAE Candidate Meets Clinical Endpoints In Phase III Trial
Latest Dyax Deal For DX-88 Should Bring In $10 Million
Latest Dyax Deal For DX-88 Should Bring In $10 Million
Dyax’s BLA For Acute Hereditary Angioedema Goes Before FDA Advisory Panel In February





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts